Not true at all the phase two back then was neither plus or minus, they stopped the trial because of Herceptin, out of the 335 woman over 200 were 3 plus, those 3 plus woman were on Herceptin which is cure so those woman our largest cohort would not get their cancer back, however our 1+, 2+ and triple negative populations where Herceptin does not work did great on our drug the data highly significant and positive but we needed another 30 million to recruit 1+2+ and triple negative patients 200 of them to offset the 200 3 plus that had the cure with Herceptin, understan this trial
Was designed in 2006 when Herceptin was a big failure otherwise we would never of included 3 plus patients, so 30 million to raise with a company just delisted and fully diluted with over 3 billion shares out not happenening so we stopped the trial, period, however highly successful in triple Negative, off the charts good, and this has all been discussed publically many many times.